Discovery of broad-spectrum bacterial polyamine detoxification inhibitors as potential antivirulence agents and antibiotic adjuvants
Moulding, P. B., Flannagan, R. S., Wong, J., Wong, J., Martin-Camara, O., Soliman, A. M., Martin-Santamaria, S., Elhenawy, W., et al.
microbiology
Quick verdict
biorxiv: screen yields spermine-synergizing inhibitors via SSAT SpeG/PaiASa; broad activity but potency-gap and SAT1/hemolysis limits mean leads need more work
Summary
This bioRxiv preprint reports two parallel chemical screens against MRSA USA300 in the presence of sub-inhibitory spermine (the Spectrum library of 2,560 compounds and 83 curated polyamine analogs), yielding six spermine synergists, with two prioritized leads: the polyamine analog OES2-0017 and the catechol isoproterenol (OES1-1087). Chemical-genomic profiling of the Nebraska transposon mutant library plus purified-enzyme assays, HPLC, thermal shift, docking and MD indicate OES2-0017 directly inhibits the spermine/spermidine acetyltransferase SpeG (IC50 34.82 uM, Ki 38.70 uM) and a newly characterized S. aureus SSAT, PaiASa, whereas OES1-1087 acts indirectly by reducing intracellular acetyl-CoA and increasing membrane fluidity. Both compounds show broad-spectrum spermine synergy that is lost in SSAT mutants, and OES2-0017 abolishes spermine-mediated protection from vancomycin, rifampicin and kanamycin, reduces Salmonella burden in macrophages, while isoproterenol lowers organ burden in a murine gastrointestinal infection model. Key limitations: a striking mismatch between in vitro enzyme potency and cellular synergy at 0.6-5 uM, marked inhibition of human SAT1 (Ki 13.03 uM), and hemolysis beginning at 160 uM versus a 20 uM MIC, so target engagement and toxicity need further work.
Review complete
Assessment at a glance
5
risk flags identified
● high 1
● medium 3
● low 1
6 strengths · 6 weaknesses · 5 author questions
AI text signal = Binoculars zero-shot detector score over 20 sampled passages (Fast-DetectGPT co-reported) — absence does not prove human authorship, and a flag does not imply misconduct.
Levels reflect verification complexity — not a quality score. Evolve never rates your paper.
Key claims under review
- OES2-0017 and OES1-1087 (isoproterenol), identified by whole-cell screens, synergize with spermine against MRSA USA300 at low micromolar concentrations.
- Both compounds disrupt polyamine detoxification by the acetyltransferases SpeG and the newly characterized PaiASa: OES2-0017 directly inhibits them, OES1-1087 indirectly by depleting intracellular acetyl-CoA and increasing membrane fluidity.
- The compounds show broad-spectrum synergy across Gram-positive and Gram-negative bacteria and Candida albicans, lost in SSAT mutants, supporting on-target activity.
- OES2-0017 acts as an antibiotic adjuvant by abolishing spermine-mediated protection from vancomycin, rifampicin and kanamycin, and shows intracellular (macrophage) antivirulence activity; OES1-1087 reduces bacterial burden in a murine gastrointestinal infection model.
- Small-scale SAR identified OES2-0017 analogs with improved bacterial-vs-human (SAT1) specificity and no detectable eukaryotic toxicity at tested ranges.
Strengths
Systematic multi-stage hit triage
Two orthogonal screens (2,560-compound Spectrum library + 83 rationally chosen polyamine analogs) under sub-MIC spermine produced 187 primary hits, narrowed to 129 after excluding known antimicrobials, then to 6 confirmed synergists by dose-response and checkerboard FICI/SynergyFinder ZIP validation (Figure 1); lead structures confirmed by NMR (Supplementary Fig. 2).
Convergent genetic and biochemical target evidence
NTML chemogenomics identified speG alongside four new spermine determinants (tcaA, cls, prmC, pyrP); synergy is lost in ΔspeG and in naturally speG- strains (COL, NCTC8325), and OES2-0017 directly inhibits SpeG (IC50 34.82±6.81 μM; Ki 38.70±6.55 μM) with HPLC confirmation of reduced N1-acetylspermine at 300 μM (Figure 3A-C).
Honest dissection of a dual mode of action
New enzyme discovery
Rigorous handling of a confounding mutant
Mechanistically grounded adjuvant experiments
Weaknesses
Unresolved enzyme-vs-cell potency gap
Weak pharmacological selectivity of the lead
Thin in vivo statistical reporting
Mechanistic causality gap for the in vivo lead
Limited spectrum breadth and strain coverage
Correctable drafting errors
Full Review Report
$1.99 · one-timeUnlock the complete preliminary analysis Evolve produced for this paper.
Report preview
Structured Review: Polyamine Detoxification Inhibitors as Antivirulence Agents and Antibiotic Adjuvants (bioRxiv 2024.10.18.618978)
The remaining sections cover Methodology Assessment, Statistical Evidence, Results & Reproducibility, Limitations & Risks, and Verdict & Recommendations.
- All 6 strengths & 6 weaknesses, analyzed in detail
- 5 risk flags with severity, section & reviewer questions
- Methods & statistical evidence assessment
- 5 questions a peer reviewer would ask
- Full six-dimension evaluation report & recommendations
One-time purchase · this paper only
One-time purchase, this paper only. AI-generated preliminary analysis — not peer review.
Frequently asked questions
What do OES2-0017 and OES1-1087 do in this paper?
They are two molecules that synergize with the polyamine spermine to inhibit bacteria, including MRSA USA300. OES2-0017 directly inhibits bacterial polyamine-detoxifying acetyltransferases (SpeG and PaiASa), while OES1-1087 - which is the approved heart drug isoproterenol - acts indirectly by lowering intracellular acetyl-CoA and increasing membrane fluidity.
Why is polyamine detoxification a good antimicrobial target?
Host tissues accumulate polyamines such as spermine during infection, and pathogens carrying detoxification enzymes like SpeG (part of the ACME element in USA300 MRSA) survive this stress and show increased virulence; blocking detoxification is proposed as an antivirulence strategy that also restores antibiotic susceptibility.
Does OES2-0017 kill bacteria on its own?
Yes, but at higher concentrations (MIC 20 μM) through a separate mechanism - membrane perturbation - rather than through SpeG inhibition. The low-dose synergy with spermine is the claimed antivirulence/adjuvant mechanism.
What are the main limitations acknowledged or evident in the study?
The in vitro enzyme Ki (~39 μM) does not match the low-micromolar whole-cell synergy, indicating unconfirmed cellular target engagement; OES2-0017 inhibits the human ortholog SAT1 at least as potently (Ki 13.03 μM) and hemolysis begins at 160 μM; and the isoproterenol in vivo result is not causally tied to SpeG inhibition.
About this review
This is an AI-generated preliminary review by Evolve.Pub, produced from the openly available text of the paper. It is not peer review and does not represent the authors' views. The canonical record of the paper is at the publisher link above.
- The extracted text is truncated with multiple '[...section omitted...]' gaps (e.g., the acetyl-CoA-quantification results and parts of the macrophage/mouse figure legend and methods), so figures could only be assessed via captions and in-text numbers.
- bioRxiv version metadata conflict: the DOI (2024.10.18.618978) implies an October 2024 posting while the embedded license block says 'this version posted September 17, 2026'; the review applies to the embedded (apparently revised) text.
- Tables/figures were unavailable as data; all numeric values cited were taken from captions and body text and could not be visually verified.
- Minor internal inconsistencies in the manuscript (e.g., 'OE2-0017' heading, strain-name typos, n-statement discrepancies) may reflect either source errors or extraction artifacts.
Go deeper on this paper
Wrote a paper? Stress-test it before reviewers do.
Upload your manuscript for the same structured scrutiny — reasoning, statistics, evidence, figures, and reproducibility.